AIMS: Fractional flow reserve (FFR) is the reference standard for the assessment of the functional significance of coronary artery stenoses, but is underutilized in daily clinical practice. We aimed to study long-term outcomes of FFR-guided percutaneous coronary intervention (PCI) in the general clinical practice. METHODS AND RESULTS: In this retrospective study, consecutive patients (n = 7358), referred for PCI at the Mayo Clinic between October 2002 and December 2009, were divided in two groups: those undergoing PCI without (PCI-only, n = 6268) or with FFR measurements (FFR-guided, n = 1090). The latter group was further classified as the FFR-Perform group (n = 369) if followed by PCI, and the FFR-Defer group (n = 721) if PCI was deferred. Clinical events were compared during a median follow-up of 50.9 months. The Kaplan-Meier fraction of major adverse cardiac events at 7 years was 57.0% in the PCI-only vs. 50.0% in the FFR-guided group (P = 0.016). Patients with FFR-guided interventions had a non-significantly lower rate of death or myocardial infarction compared with those with angiography-guided interventions [hazard ratio (HR): 0.85, 95% CI: 0.71-1.01, P = 0.06]; the FFR-guided deferred-PCI strategy was independently associated with reduced rate of myocardial infarction (HR: 0.46, 95% CI: 0.26-0.82, P = 0.008). After excluding patients with FFR of 0.75-0.80 and deferring PCI, the use of FFR was significantly associated with reduced rate of death or myocardial infarction (HR: 0.80, 95% CI: 0.66-0.96, P = 0.02). CONCLUSION: In the contemporary practice, an FFR-guided treatment strategy is associated with a favourable long-term outcome. The current study supports the use of the FFR for decision-making in patients undergoing cardiac catheterization.
AIMS: Fractional flow reserve (FFR) is the reference standard for the assessment of the functional significance of coronary artery stenoses, but is underutilized in daily clinical practice. We aimed to study long-term outcomes of FFR-guided percutaneous coronary intervention (PCI) in the general clinical practice. METHODS AND RESULTS: In this retrospective study, consecutive patients (n = 7358), referred for PCI at the Mayo Clinic between October 2002 and December 2009, were divided in two groups: those undergoing PCI without (PCI-only, n = 6268) or with FFR measurements (FFR-guided, n = 1090). The latter group was further classified as the FFR-Perform group (n = 369) if followed by PCI, and the FFR-Defer group (n = 721) if PCI was deferred. Clinical events were compared during a median follow-up of 50.9 months. The Kaplan-Meier fraction of major adverse cardiac events at 7 years was 57.0% in the PCI-only vs. 50.0% in the FFR-guided group (P = 0.016). Patients with FFR-guided interventions had a non-significantly lower rate of death or myocardial infarction compared with those with angiography-guided interventions [hazard ratio (HR): 0.85, 95% CI: 0.71-1.01, P = 0.06]; the FFR-guided deferred-PCI strategy was independently associated with reduced rate of myocardial infarction (HR: 0.46, 95% CI: 0.26-0.82, P = 0.008). After excluding patients with FFR of 0.75-0.80 and deferring PCI, the use of FFR was significantly associated with reduced rate of death or myocardial infarction (HR: 0.80, 95% CI: 0.66-0.96, P = 0.02). CONCLUSION: In the contemporary practice, an FFR-guided treatment strategy is associated with a favourable long-term outcome. The current study supports the use of the FFR for decision-making in patients undergoing cardiac catheterization.
Authors: G J Bech; B De Bruyne; N H Pijls; E D de Muinck; J C Hoorntje; J Escaned; P R Stella; E Boersma; J Bartunek; J J Koolen; W Wijns Journal: Circulation Date: 2001-06-19 Impact factor: 29.690
Authors: R F Davies; A D Goldberg; S Forman; C J Pepine; G L Knatterud; N Geller; G Sopko; C Pratt; J Deanfield; C R Conti Journal: Circulation Date: 1997-04-15 Impact factor: 29.690
Authors: B De Bruyne; N H Pijls; J Bartunek; K Kulecki; J W Bech; H De Winter; P Van Crombrugge; G R Heyndrickx; W Wijns Journal: Circulation Date: 2001-07-10 Impact factor: 29.690
Authors: Blaithnead Murtagh; Stuart Higano; Ryan Lennon; Verghese Mathew; David R Holmes; Amir Lerman Journal: Am Heart J Date: 2003-07 Impact factor: 4.749
Authors: Bernard De Bruyne; Nico H J Pijls; Bindu Kalesan; Emanuele Barbato; Pim A L Tonino; Zsolt Piroth; Nikola Jagic; Sven Möbius-Winkler; Sven Mobius-Winckler; Gilles Rioufol; Nils Witt; Petr Kala; Philip MacCarthy; Thomas Engström; Keith G Oldroyd; Kreton Mavromatis; Ganesh Manoharan; Peter Verlee; Ole Frobert; Nick Curzen; Jane B Johnson; Peter Jüni; William F Fearon Journal: N Engl J Med Date: 2012-08-27 Impact factor: 91.245
Authors: N H Pijls; B De Bruyne; K Peels; P H Van Der Voort; H J Bonnier; J J Bartunek J Koolen; J J Koolen Journal: N Engl J Med Date: 1996-06-27 Impact factor: 91.245
Authors: Morteza Safi; Vahid Eslami; Mohammad Hasan Namazi; Hossain Vakili; Habib Saadat; Saeid Alipourparsa; Ali Adibi; Mohammad Reza Movahed Journal: Int J Angiol Date: 2015-12-31
Authors: Catherine Pagiatakis; Jean-Claude Tardif; Philippe L L'Allier; Rosaire Mongrain Journal: Med Biol Eng Comput Date: 2017-05-13 Impact factor: 2.602
Authors: Tim P van de Hoef; Martijn A van Lavieren; José P S Henriques; Jan J Piek; Bimmer E P M Claessen Journal: Curr Treat Options Cardiovasc Med Date: 2014-04
Authors: Vicente Taasan; Anita Wokhlu; Michael V Taasan; Raman S Dusaj; Ajay Mehta; Steven Kraft; David Winchester; David Wymer Journal: J Nucl Cardiol Date: 2015-12-30 Impact factor: 5.952
Authors: Shu Yokota; Jan Paul Ottervanger; Mohamed Mouden; Jorik R Timmer; Siert Knollema; Pieter L Jager Journal: J Nucl Cardiol Date: 2014-01-28 Impact factor: 5.952
Authors: Jing Li; Charanjit S Rihal; Yoshiki Matsuo; Muhamad Y Elrashidi; Andreas J Flammer; Moo-Sik Lee; Andrew Cassar; Ryan J Lennon; Joerg Herrmann; Malcolm R Bell; David R Holmes; John F Bresnahan; Qi Hua; Lilach O Lerman; Amir Lerman Journal: Circ Cardiovasc Interv Date: 2013-10-22 Impact factor: 6.546
Authors: Tim P van de Hoef; Martijn Meuwissen; Javier Escaned; Justin E Davies; Maria Siebes; Jos A E Spaan; Jan J Piek Journal: Nat Rev Cardiol Date: 2013-06-11 Impact factor: 32.419